2021
Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data
Yang SC, Wang JD, Wang SY. Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data. Scientific Reports 2021, 11: 12180. PMID: 34108586, PMCID: PMC8190256, DOI: 10.1038/s41598-021-91852-6.Peer-Reviewed Original ResearchConceptsLead-time biasNational Lung Screening TrialStage shiftStage IALife expectancyCancer patientsLung cancerCalendar yearNationwide cancer registryBenefits of screeningLung cancer patientsReal-world studyLung cancer diagnosisMean life expectancyTomography screeningCancer RegistryLE gainsCancer screeningEarly diagnosisScreening TrialGeneral populationSame pathologyYounger agePathologyCancer diagnosis
2020
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnthracyclinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicBreast NeoplasmsCase-Control StudiesCost-Benefit AnalysisCross-Linking ReagentsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMiddle AgedNeoadjuvant TherapyPaclitaxelQuality-Adjusted Life YearsReceptor, ErbB-2TrastuzumabTubulin ModulatorsUnited StatesConceptsErbB2-positive breast cancerAdjuvant treatment strategiesAdjuvant T-DM1Pathologic complete responseT-DM1Treatment strategiesBreast cancerKATHERINE trialResidual diseaseNeoadjuvant regimenHigher health benefitsHealth care payer perspectiveAdjuvant trastuzumab emtansineAnthracycline/cyclophosphamideDifferent adjuvant therapiesFlatiron Health databaseIncremental cost-effectiveness ratioNeoadjuvant treatment optionsHealth benefitsPositive breast cancerCare payer perspectiveCost-effectiveness ratioBase-case analysisDecision analytic modelH. Patients
2019
Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis.
Wang SY, Chen T, Dang W, Mougalian SS, Evans SB, Gross CP. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis. Journal Of The National Comprehensive Cancer Network 2019, 17: 39-46. PMID: 30659128, DOI: 10.6004/jnccn.2018.7077.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantClinical Decision-MakingConnecticutCost-Benefit AnalysisDecision Support TechniquesFemaleGene Expression ProfilingGenetic TestingHumansMarkov ChainsMastectomyMiddle AgedModels, StatisticalNeoplasm Recurrence, LocalPrevalencePrognosisQuality-Adjusted Life YearsRisk AssessmentConceptsIncremental cost-effectiveness ratioClinical risk groupsQuality-adjusted life yearsHigh-risk groupLow-risk groupOncotype DXRisk groupsBreast cancerLymph node-negative breast cancerDifferent clinical risk groupsLow-risk breast cancerNode-negative breast cancerIntermediate-risk groupRecurrence score (RS) distributionConnecticut Tumor RegistryER-positive diseaseUS payer perspectivePopulation-based dataCost-effectiveness ratioProbabilistic sensitivity analysesCost-effectiveness analysisODX resultsClinical characteristicsMost patientsPatient age
2017
Cost-Effectiveness of Multidisciplinary Management Program and Exercise Training Program in Heart Failure
Dang W, Yi A, Jhamnani S, Wang SY. Cost-Effectiveness of Multidisciplinary Management Program and Exercise Training Program in Heart Failure. The American Journal Of Cardiology 2017, 120: 1338-1343. PMID: 28842145, DOI: 10.1016/j.amjcard.2017.06.071.Peer-Reviewed Original ResearchConceptsMultidisciplinary management programIncremental cost-effectiveness ratioUsual careLife yearsHeart failureExercise training programHealthcare payer perspectiveCost-effectiveness ratioProbabilistic sensitivity analysesCost-effectiveness thresholdCurrent cost-effectiveness thresholdsPayer perspectiveHealthcare costsHealth outcomesTraining programSocietal perspectiveSignificant healthFinancial burdenPatientsManagement programETPFailureYearsCareCost-Effectiveness Study of Criteria for Screening Cerebrospinal Fluid To Determine the Need for Herpes Simplex Virus PCR Testing
Hauser RG, Campbell SM, Brandt CA, Wang S. Cost-Effectiveness Study of Criteria for Screening Cerebrospinal Fluid To Determine the Need for Herpes Simplex Virus PCR Testing. Journal Of Clinical Microbiology 2017, 55: 1566-1575. PMID: 28298450, PMCID: PMC5405275, DOI: 10.1128/jcm.00119-17.Peer-Reviewed Original ResearchConceptsCerebrospinal fluidHerpes simplex virus (HSV) central nervous system (CNS) infectionPCR testingCentral nervous system infectionCSF white blood cellsHSV PCR testingNervous system infectionLarge health care systemWhite blood cellsCost-effectiveness studiesHealth care systemDecision analysis modelHSV encephalitisCNS infectionSystem infectionHSV infectionAbsence of markersImmunocompetent hostsNecessary diagnostic testsOrgan transplantsPatient careDiagnostic testsBlood cellsCare systemPCR test
2014
Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer
Sen S, Wang SY, Soulos PR, Frick KD, Long JB, Roberts KB, Yu JB, Evans SB, Chagpar AB, Gross CP. Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer. Journal Of The National Cancer Institute 2014, 106: dju008. PMID: 24598714, PMCID: PMC3982782, DOI: 10.1093/jnci/dju008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrachytherapyBreast NeoplasmsComorbidityCost-Benefit AnalysisFemaleHealth ExpendituresHumansLife ExpectancyMedicareNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeQuality-Adjusted Life YearsRadiotherapy, Intensity-ModulatedRisk AssessmentRisk FactorsSampling StudiesSEER ProgramUnited StatesConceptsExternal beam radiation therapyIncremental cost-effectiveness ratioQuality-adjusted life yearsBreast cancerOlder womenRadiation therapyEnd Results-Medicare databaseRisk breast cancerBeam radiation therapyCost-effectiveness ratioNewer radiation therapy modalitiesQuality of lifeRadiation therapy modalitiesLocal recurrenceTrial criteriaRT modalityTherapy modalitiesLife yearsCancerIncremental costTherapyWomenBaseline stateNew modality
2010
Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis
Wang SY, Kuntz K, Tuttle T, Kane R. Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis. Breast Cancer Research And Treatment 2010, 124: 393-402. PMID: 20848183, DOI: 10.1007/s10549-010-1166-7.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingDecision Support TechniquesFemaleHumansMarkov ChainsMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalPatient PreferencePatient SelectionQuality-Adjusted Life YearsRadiotherapy, AdjuvantRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsBreast-conserving surgeryQuality-adjusted life yearsRadiation therapyMargin statusDuctal carcinomaRT side effectsDecision-analytic Markov modelOne-way sensitivity analysesImportance of patientsProbabilistic sensitivity analysesDCIS treatmentInvasive recurrenceSalvage mastectomyOptimal treatmentHypothetical cohortTreatment decisionsLifetime horizonSide effectsLife yearsDCISPatientsWomenCarcinomaTreatment